硫糖铝混悬液辅助治疗对隆起糜烂性胃炎患者的效果

Effect of Sucralfate Suspension in Adjuvant Treatment in Patients with Raised Erosive Gastritis

目的:探讨硫糖铝混悬液辅助治疗对隆起糜烂性胃炎(REG)患者的效果。方法:选取泉州市光前医院2019年5月至2020年5月期间收治的94例REG患者,采用随机数字表法分为对照组与观察组,各47例。对照组给予奥美拉唑治疗,观察组在对照组基础上给予硫糖铝混悬液辅助治疗,观察两组患者炎症因子水平、胃蛋白酶情况、胃黏膜水平及不良反应。结果:治疗前与治疗8周后,两组间肿瘤坏死因子-α(TNF-α)、白细胞介素-10(IL-10)及白细胞介素-8(IL-8)比较,差异均无统计学意义(P>0.05);治疗8周后,两组患者TNF-α、IL-10及IL-8水平均下降,差异具有统计学意义(P<0.05)。治疗8周后,两组患者胃泌素-17(GAS-17)、胃蛋白酶原Ⅰ(PGⅠ)、PGⅠ/PGⅡ(PGR)水平均明显高于治疗前,胃蛋白酶原Ⅱ(PGⅡ)值低于治疗前,且观察组GAS-17、PGⅠ、PGR水平均高于对照组,PGⅡ值低于对照组,差异均具有统计学意义(P<0.05)。治疗8周后,两组患者Ki-67、成纤维细胞生长因子(bFGF)、表皮生长因子(EGF)水平均明显低于治疗前,且观察组患者Ki-67、bFGF、EGF水平均低于对照组,差异具有统计学意义(P<0.05)。观察组患者不良反应发生率为8.51%,对照组为12.77%,组间比较,差异无统计学意义(P>0.05)。结论:硫糖铝混悬液辅助治疗应用于REG可有效改善患者胃黏膜状况及胃蛋白酶水平,降低炎症因子水平,且不增加药物不良反应。

Objective To investigate the effect of sucralfate suspension in the adjuvant treatment in patients of raised erosive gastritis(REG).Methods A total of 94 REG patients admitted to Quanzhou Guangqian Hospital from May 2019 to May 2020 were selected and divided into control group and observation group by random number table method,with 47 cases in each group.The control group was treated with omeprazole,and the observation group was additionally treated with sucralfate suspension.The levels of inflammatory factors,pepsin,gastric mucosa level and adverse reactions in the two groups were observed.Results There were no significant differences in tumor necrosis factor-α(TNF-α),interleukin-10(IL-10)and interleukin-8(IL-8)between the two groups before treatment and 8 weeks after treatment(P>0.05).After 8 weeks of treatment,the levels of TNF-α,IL-10 and IL-8 in the two groups were decreased,the differences were statistically significant(P<0.05).After 8 weeks of treatment,the levels of gastrin-17(GAS-17),pepsinogenⅠ(PGⅠ)and PGⅠ/PGⅡ(PGR)in the two groups were significantly higher than before treatment,while the level of pepsinogenⅡ(PGⅡ)was lower than before treatment.The levels of GAS-17,PGⅠ and PGR in observation group were higher than control group,while the PGⅡ value was lower than control group.The differences were statistically significant(P<0.05).After 8 weeks of treatment,the levels of KI-67,fibroblast growth factor(bFGF)and epidermal growth factor(EGF)in the two groups were significantly lower than before,and the levels of KI-67,bFGF and EGF in observation group were lower than control group,the differences were statistically significant(P<0.05).The incidence of adverse reactions was 8.51% in the observation group and 12.77% in the control group,and there was no significant difference between the two groups(P>0.05).Conclusion Sucralfate suspension can effectively improve the gastric mucosal status and gastric protein level of patients with REG,reduce the level of inflammatory factors,and do not increase the adverse drug reactions.